Chapters Transcript Video DESTINY-Breast09 Presented by Sara Tolaney, MD, MPH. Dr. Sara Tolaney of Dana-Farber shares pivotal results from the DESTINY-Breast09 phase 3 trial. So all we've had Taxanes plus trastuzumab and Pertuzumab as the first line standard of care for metastatic HER2 positive breast cancer for well over a decade, we do know that unfortunately patients do progress usually within 2 years on that first line treatment, suggesting that we do need to do better. We've seen remarkable progress with the introduction of Trustuzumabdoxticin or TDXD for metastatic HER2 positive disease where it has really. Dramatically improved outcomes for those patients with pre-treated metastatic HER2 positive breast cancer. So there's been a large interest to see if we could move TDXD into that front line setting. So the Destiny Breast 09 study was designed to compare TDXD with or without Pertuzumab to THP. With the primary endpoint being progression free survival, and what we saw was that at the time of an interim analysis, the combination of TDHD and Pertuzumab did lead to a significant improvement in PFS when compared to THP. The strict interim analysis criteria for significance were not met yet for the TDXD monotherapy arm, so what was presented is just the combination arm of TDXD and Pertuzumab compared to THP. So what we saw was that the combination of TDXD and protuzumab. Was associated with a significant improvement in progression free survival with an improvement going from 26.9 months to a little over 40 months consistent with the hazard ratio of 0.56. So this near doubling of progression free survival really suggests that the combination of TDXD and Pertuzumab may be a new standard of care option for patients who have metastatic HER2 positive breast cancer. Published June 11, 2025 Created by Related Presenters
